Long term BMS exec Johanna Mercier joins Gilead as new Chief Commercial Officer
pharmafile | May 30, 2019 | News story | Medical Communications, Sales and Marketing | BMS, Bristol-Myers Squibb, Gilead, cco, commercial, pharma
Gilead Sciences have said Bristol-Myers Squibb exec Johanna Mercier will be the firm’s new Chief Commercial Officer.
In her new role Mercier will join Gilead’s senior leadership team when she takes over the California firm’s commercial operations on July 1.
Mercier, who served with BMS for more than ten years, brings a wealth of experience to the role. The experienced executive holds a degree in Biology from the University of Montreal and an MBA from Concordia University.
Having held leadership positions in locations around the world, Mercier brings with her experience in therapeutic areas including oncology, inflammation and neuroscience from positions in countries including the United Kingdom, France and the United States.
In her most recent position Mercier served as President and Head of BMS’ Large Markets division, which includes the United States, France, Germany and Japan.
“I believe that Johanna has the skills to continue to strengthen our performance and position Gilead for long-term success, building on the great talent I have seen across the organization since joining the company several months ago,” said Daniel O’Day, Chairman and Chief Executive Officer.
“She is a talented leader with a deep understanding of the pharmaceutical industry, across therapeutic markets and geographies, as well as a proven ability to input the commercial perspective into development strategies. I look forward to welcoming her to Gilead and to working closely with her to ensure optimal commercial delivery that puts the needs of patients at the center of all we do.”
Commenting on her own appointment Mericer said: “Gilead is an organization that is deeply committed to bringing forward transformational medicines for patients with serious illnesses. Throughout my career, I have worked to improve care for people with unmet medical needs and I am excited to join a company that shares my commitment to doing what is right for patients – and to advancing and commercializing important new medicines.”
Louis Goss
Related Content
Pharma sees climate disruption as growing supply-chain risk
Nine in ten pharmaceutical companies across the UK and G7 countries expect climate-related disruption to …
AI in pharma: From lab development to patient impact
In the decade to 2025, AI use in vaccine development has increased markedly but is …
BMS’ Opdivo/Yervoy combination accepted by Scottish Medicines Consortium for colorectal cancer
Bristol Myers Squibb (BMS) has announced that its Opdivo (nivolumab) has been accepted, in combination …
